scispace - formally typeset
Open AccessJournal ArticleDOI

An open-label, 6-month study of allopurinol safety in gout: The LASSO study

Michael Becker, +6 more
- 01 Oct 2015 - 
- Vol. 45, Iss: 2, pp 174-183
TLDR
This large multicenter study of allopurinol dose-titration strategy was well tolerated, without new safety signals emerging over 6 months, but despite encouragement to treat to target, significant proportions of patients did not achieve target sUA.
About: 
This article is published in Seminars in Arthritis and Rheumatism.The article was published on 2015-10-01 and is currently open access. It has received 77 citations till now. The article focuses on the topics: Allopurinol hypersensitivity syndrome & Allopurinol.

read more

Citations
More filters
Journal ArticleDOI

Gout: An old disease in new perspective – A review

Gaafar Ragab, +2 more
- 01 Sep 2017 - 
TL;DR: Gout is a picturesque presentation of uric acid disturbance as mentioned in this paper, it is the most well understood and described type of arthritis. Diagnosis is based on laboratory and radiological features, the gold standard of diagnosis is identification of characteristic MSU crystals in the synovial fluid using polarized light microscopy.
Journal ArticleDOI

Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)

Kenneth G. Saag, +8 more
- 01 Jan 2017 - 
TL;DR: The Combining Lesinurad with Allopurinol Standard of Care in Inadequate Responders (CLEAR 1) study, a 12‐month, multicenter, randomized, double‐blind, placebo‐controlled phase III trial, was conducted to investigate daily lesinur ad added to allopur inol versus placebo plus allopURinol in patients with serum urate (UA) levels above a target of <6.0 mg/dl.
Journal ArticleDOI

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)

Thomas Bardin, +9 more
- 01 May 2017 - 
TL;DR: Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopURinol-alone therapy and lesinur ad 200 mg was generally well tolerated in patients with gout warranting additional therapy.
Journal ArticleDOI

Gout: state of the art after a decade of developments.

Tristan Pascart, +2 more
- 13 Mar 2018 - 
TL;DR: It is emphasized that the current epidemiology of gout indicates a rising prevalence worldwide, not only in Western countries but also in Southeast Asia, in close relationship with the obesity and metabolic syndrome epidemics.
Journal ArticleDOI

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

Nicola Dalbeth, +10 more
- 01 Sep 2017 - 
TL;DR: To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12‐month phase III trial in patients with tophaceous gout.
References
More filters
Journal ArticleDOI

Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.

Yanyan Zhu, +2 more
- 01 Oct 2011 - 
TL;DR: The findings from nationally representative samples of US adults suggest that the prevalence of both gout and hyperuricemia remains substantial and may have increased over the past 2 decades, which is likely related to increasing frequencies of adiposity and hypertension.
Journal ArticleDOI

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Dinesh Khanna, +32 more
- 01 Oct 2012 - 
TL;DR: DINESH KHanNA, JOHN D. FITZGERALD, PUJA P. KHANNA, SANGMEE BAE, MANJIT K. SINGH, TUHINA NEOGI, MICHAEL H. PILLINGER, JOAN MERILL, SUSAN LEE, SHRADDHA PRAKASH, MARIAN KALDAS, MANEESH GOGIA, FERNANDO PEREZ-RUI
Journal ArticleDOI

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)

Weiya Zhang, +19 more
- 01 Oct 2006 - 
TL;DR: 12 key recommendations for management of gout were developed, using a combination of research based evidence and expert consensus, based on a Delphi consensus approach.
Journal ArticleDOI

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

Michael Becker, +7 more
- 08 Dec 2005 - 
TL;DR: Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in all groups andFebuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily doses of 300 mg in lowering serum urate.
Journal ArticleDOI

2016 updated EULAR evidence-based recommendations for the management of gout

Pascal Richette, +23 more
- 01 Jun 2014 - 
TL;DR: In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at the predefined urate target to cure the disease.
Related Papers (5)

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Dinesh Khanna, +32 more
- 01 Oct 2012 - 

2016 updated EULAR evidence-based recommendations for the management of gout

Pascal Richette, +23 more
- 01 Jun 2014 - 

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

Michael Becker, +7 more
- 08 Dec 2005 - 

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

H. Ralph Schumacher, +8 more
- 15 Nov 2008 - 

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Michael Becker, +6 more
- 06 Apr 2010 -